OOIR: Observatory of International Research

Papers

(The TQCC of Altex-Alternatives to Animal Experimentation is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
Alternative Methods in Science: Towards Fluidic Systems	51
Application of high-throughput transcriptomics for mechanism-based biological read-across of short-chain carboxylic acid analogues of valproic acid_suppl1	33
Intestinal in vitro transport assay combined with physiologically based kinetic modeling as a tool to predict bile acid levels in vivo_suppl1	29
Animal research ethics as interaction of research ethics, animal ethics, and (animal protection) law	23
Systematic analysis of read-across adaptations in testing proposal evaluations by the European Chemicals Agency	18
Systematic analysis of read-across adaptations in testing proposal evaluations by the European Chemicals Agency_suppl5	12
Determining a point of departure for skin sensitization potency and quantitative risk assessment of fragrance ingredients using the GARDskin dose-response assay_suppl1	11
The effect of surfactants and film-forming polymers on pulmonary surfactant function measured in vitro is dose rate dependent_suppl	9
Sensitivity analysis and quality indicators for an in vitro oral irritation assay	9
Validation of an Endopep-suspension immunoassay for the diagnostics of human botulism_suppl	8
Integrated skin sensitization assessment based on OECD methods (I): Deriving a point of departure for risk assessment	8
Validation of the monocyte activation test with three therapeutic monoclonal antibodies	8
Technical framework for enabling high-quality measurements in new approach methodologies (NAMs)	7
REACH out-numbered! The future of REACH and animal numbers	7
Off to a good start? Review of the predictivity of reactivity methods modelling the molecular initiating event of skin sensitization	7
Developmental neurotoxicity (DNT): A call for implementation of new approach methodologies for regulatory purposes: Summary of the 5th International Conference on DNT Testing	7
Integrated skin sensitization assessment based on OECD methods (I): Deriving a point of departure for risk assessment_suppl4	7
A sensitive cell-based assay for testing potency of Botulinum neurotoxin type A	6
Mapping out strategies to further develop human-relevant, new approach methodology (NAM)-based developmental neurotoxicity (DNT) testing	6
E-validation – Unleashing AI for validation	6
Making safety decisions for a sunscreen active ingredient using next-generation risk assessment: Benzophenone-4 case study	6
Predicting Acute Oral Toxicity Using AcutoX: An Animal Product-Free and Metabolically Relevant Human Cell-Based Test	6
The long way from raw data to NAM-based information: Overview on data layers and processing steps	6
Microphysiological endothelial models to characterize subcutaneous drug absorption_suppl	6
Beyond Animal Testing Index: Benchmarking tool for a world beyond animal testing_suppl4	6

Protectiveness of NAM-based hazard assessment – which testing scope is required?_suppl1	5
Chemical selection for the Thyroid Validation Study coordinated by EURL ECVAM and involving EU-NETVAL laboratories_suppl3	5
What does “success” look like in compliance check decisions by the European Chemicals Agency? The curious cases of accepted read-across adaptations	5
Developing a global education hub for animal-free innovation_suppl	5
Exploring the synergy of CRISPR and microphysiological systems	5
COVID-19 through Adverse Outcome Pathways: Building networks to better understand the disease – 3rd CIAO AOP Design Workshop	5
Mapping physiology: A systems biology approach for the development of alternative methods in toxicology	5
Non-animal approaches – Concept, validation, and regulatory acceptance: The fourth Asian Congress of Alternatives to Animal Experiments (4ACAAE) and the seventh Annual Meeting of the Society for Alter	5
A human osteoarthritis mimicking goat cartilage explant-based disease model for drug screening_suppl	4
Systematic analysis of read-across adaptations in testing proposal evaluations by the European Chemicals Agency_suppl2	4
Investigation of the publication rate of recent research projects using non-human primates in France	4
Women in Alternatives	4
The Virtual Human Platform for Safety Assessment (VHP4Safety) project: Next generation chemical safety assessment based on human data	4
Assessment of a 3D neural spheroid model to detect pharmaceutical-induced neurotoxicity	4
Designing a national strategy to enable human-relevant research in India: A multistakeholder roundtable meeting report	4
The Alarming Consequences of Workforce Reductions at the FDA, EPA, NIH and CDC in the United States	4
Systematic analysis of read-across adaptations in testing proposal evaluations by the European Chemicals Agency_suppl6	4
3Rs: Progress or a fig leaf?	4
Integrated skin sensitization assessment based on OECD methods (II): Hazard and potency by combining kinetic peptide reactivity and the “2 out of 3” Defined Approach_suppl4	4
In vitro-based prediction of human plasma concentrations of food-related compounds_suppl1	4
Determining a point of departure for skin sensitization potency and quantitative risk assessment of fragrance ingredients using the GARDskin dose-response assay_suppl3	3
A path forward advancing microphysiological systems	3
Incorporating new approach methodologies into regulatory nonclinical pharmaceutical safety assessment	3
Beyond chemicals: Opportunities and challenges of integrating non-chemical stressors in adverse outcome pathways	3
ALTEX Proceedings TIERethik Corrigendum to Incorporating new approach methodologies into regulatory nonclinical pharmaceutical safety assessment	3
From cellular perturbation to probabilistic risk assessments	3
Assessment of developmental neurotoxicology-associated alterations in neuronal architecture and function using Caenorhabditis elegans_suppl	3
Determining a point of departure for skin sensitization potency and quantitative risk assessment of fragrance ingredients using the GARDskin dose-response assay	3
Role of standards and funding in accelerating the development and use of microphysiological systems	3
Material-mediated pyrogens in medical devices: Myth or reality?_suppl2	3
Linking nanomaterial-induced mitochondrial dysfunction to existing adverse outcome pathways for chemicals_suppl1	2
Data-driven derivation of an adverse outcome pathway linking vascular endothelial growth factor receptor (VEGFR), endocrine disruption, and atherosclerosis_suppl1	2
Human relevant frontiers in drug safety and efficacy	2
Biology-inspired dynamic microphysiological system approaches to revolutionize basic research, healthcare and animal welfare	2
What does “success” look like in compliance check decisions by the European Chemicals Agency? The curious cases of accepted read-across adaptations_suppl7	2
Integrated skin sensitization assessment based on OECD methods (II): Hazard and potency by combining kinetic peptide reactivity and the “2 out of 3” Defined Approach_suppl2	2
Comparative evaluation of rat and human in vitro assays for evaluation of thyroid toxicity_suppl1	2
COVID-19 through Adverse Outcome Pathways: Building networks to better understand the disease – 3rd CIAO AOP Design Workshop_suppl	2
Evaluation of 147 perfluoroalkyl substances for immunotoxic and other (patho)physiological activities through phenotypic screening of human primary cells_suppl2	2
Qualitative and quantitative concentration-response modelling of gene co-expression networks to unlock hepatotoxic mechanisms for next generation chemical safety assessment	2
How to formulate hypotheses and IATA to support grouping and read-across of nanoforms	2
What does “success” look like in compliance check decisions by the European Chemicals Agency? The curious cases of accepted read-across adaptations_suppl6	2
Novel prediction models for genotoxicity based on biomarker genes in human HepaRGTM cells_suppl2	2
Transition to animal-free science: Phasing out animal experiments, phasing in innovation	2
Grouping of UVCB substances with dose-response transcriptomics data from human cell-based assays_suppl	2
Identifying candidate reference chemicals for in vitro testing of the retinoid pathway for predictive developmental toxicity_suppl	2
The SCAHT Adverse Outcome Pathway (AOP)_HUB: A hands-on platform for information exchange, sharing, and developing AOPs	2
Building confidence in PBK model predictions in the absence of human kinetic data: Benzophenone-4 case study_suppl1	2
Proceedings of a workshop to address animal methods bias in scientific publishing_suppl	2
Micro-replace systems	2

Integrated skin sensitization assessment based on OECD methods (II): Hazard and potency by combining kinetic peptide reactivity and the “2 out of 3” Defined Approach_suppl3	1
Integrated skin sensitization assessment based on OECD methods (III): Adding human data to the assessment_suppl1	1
Integrated skin sensitization assessment based on OECD methods (I): Deriving a point of departure for risk assessment_suppl3	1
The impact of biostatistics on hazard characterization using in vitro developmental neurotoxicity assays	1
A sensitive cell-based assay for testing potency of Botulinum neurotoxin type A_suppl	1
Impact of gut permeability on estimation of oral bioavailability for chemicals in commerce and the environment	1
Linking nanomaterial-induced mitochondrial dysfunction to existing adverse outcome pathways for chemicals_suppl2	1
Next-generation risk assessment of chemicals – Rolling out a human-centric testing strategy to drive 3R implementation: The RISK-HUNT3R project perspective	1
Impact of in vitro experimental variation in kinetic parameters on physiologically based kinetic (PBK) model simulations_suppl1	1
Guidance for Good In Vitro Reporting Standards (GIVReSt) – A draft for stakeholder discussion and background documentation	1
Grouping of UVCB substances with dose-response transcriptomics data from human cell-based assays	1
Review on organ-on-chips for medicines safety assessment: A European regulatory perspective_suppl1	1
Ways to broaden the awareness, consideration and adoption of new approach methodologies (NAMs)	1
Comparison of human recombinant protein coatings and fibroblast-ECM to Matrigel for induced pluripotent stem cell culture and renal podocyte differentiation_suppl1	1
The benefits of validation of methods for toxicity testing outweigh its costs	1
On the usefulness of animals as a model system (part II): Considering benefits within distinct use domains	1
A human iPSC-based in vitro neural network formation assay to investigate neurodevelopmental toxicity of pesticides_suppl2	1
Development of a network of carcinogenicity adverse outcome pathways and its employment as an evidence framework for safety assessment	1
Material-mediated pyrogens in medical devices: Myth or reality?_suppl1	1
Predictive alternative methods for assessing biocompatibility of dental materials: A NIST-NIDCR workshop report	1
Building confidence in PBK model predictions in the absence of human kinetic data: Benzophenone-4 case study	1
Perspectives on the evaluation and adoption of complex in vitro models in drug development: Workshop with the FDA and the pharmaceutical industry (IQ MPS Affiliate)	1
3 Days for 3Rs 2023: Refinement, reduction, replacement	1
Data-driven derivation of an adverse outcome pathway linking vascular endothelial growth factor receptor (VEGFR), endocrine disruption, and atherosclerosis	1
Predictive performance of next generation human physiologically based kinetic (PBK) model predictions based on in vitro and in silico input data_suppl2	1
Novel prediction models for genotoxicity based on biomarker genes in human HepaRGTM cells_suppl1	1
Open-source human skin model with an in vivo-like barrier for drug testing_suppl	1
Phase-out planning for animal experimentation: A definition, an argument, and seven action points	1
Virtual control groups in non-clinical toxicology – A replicability challenge	1
Ready for regulatory use: NAMs and NGRA for chemical safety assurance	1